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The mitochondrial proapoptotic protein Smac/DIABLO has recently been shown to potentiate apoptosis by
counteracting the antiapoptotic function of the inhibitor of apoptosis proteins (IAPs). In response to apoptotic
stimuli, Smac is released into the cytosol and promotes caspase activation by binding to IAPs, thereby blocking
their function. These observations have suggested that Smac is a new regulator of apoptosis. To better
understand the physiological function of Smac in normal cells, we generated Smac-deficient (Smac/) mice by
using homologous recombination in embryonic stem (ES) cells. Smac/ mice were viable, grew, and matured
normally and did not show any histological abnormalities. Although the cleavage in vitro of procaspase-3 was
inhibited in lysates of Smac/ cells, all types of cultured Smac/ cells tested responded normally to all
apoptotic stimuli applied. There were also no detectable differences in Fas-mediated apoptosis in the liver in
vivo. Our data strongly suggest the existence of a redundant molecule or molecules capable of compensating
for a loss of Smac function.
Apoptosis, or programmed cell death (PCD), is a physiolog-
ical cell suicide program essential for both embryonic devel-
opment and the maintenance of tissue homeostasis in multi-
cellular organisms (6, 11, 13). The family of cysteine proteases
known as caspases are key components of mammalian PCD
(1). Caspases are expressed in cells as inactive precursors,
which are activated by proteolytic processing (22, 26). Two
classes of caspases, initiators and effectors, are involved in
mammalian apoptosis (3). Activated initiator caspases, such as
caspase 8 and caspase 9, cleave the precursor forms of effector
caspases, such as caspases 3, 6, and 7. Activated effector
caspases in turn cleave a specific set of cellular substrates
resulting in the biochemical and morphological changes asso-
ciated with the apoptotic phenotype (26).
The activation of initiator caspases is thought to irreversibly
trigger the caspase cascade, necessitating that caspase activa-
tion be tightly regulated by layered control mechanisms.
Among the growing number of cellular proteins that have been
shown to regulate caspase activation and activity are the IAPs,
including c-IAP1, c-IAP2, XIAP, and survivin. These proteins
have been reported to block both death receptor- and mito-
chondrially-mediated apoptotic pathways by directly inhibiting
initiator and effector caspases (4, 28).
Smac/DIABLO, a mitochondrial protein released into the
cytosol in response to apoptotic stimuli, was recently found to
promote caspase activation by eliminating IAP function (5,
29). Smac binds to most known human IAP family members
and relieves their inhibition of caspase activity. The N-terminal
20 amino acids of the mature Smac protein are crucial for
Smac-IAP interaction, and removal of this region completely
abrogates the ability of Smac to bind to XIAP (2, 33). Since
Smac blocks IAP activity, it has been proposed that Smac is a
mammalian functional homologue of the Drosophila proapo-
ptotic proteins Reaper, Grim, and Hid (9, 20, 34). This hypoth-
esis is bolstered by the finding that the first four N-terminal
residues of Smac, which recognize a surface groove on BIR3,
are also conserved in the Drosophila proteins (33).
In this study, we generated gene-targeted Smac-deficient
mice and studied the apoptosis of Smac-deficient cells in vitro
and in vivo. We demonstrate that several types of Smac-defi-
cient primary cells respond normally to a broad range of apo-
ptotic stimuli. Normal apoptosis is also induced in the liver in
vivo . These lines of evidence strongly suggest the existence of
molecules and pathways that can circumvent the loss of Smac.
MATERIALS AND METHODS
ES cell culture. E14K embryonic stem (ES) cells from 129/Ola mice were
maintained on a layer of mitomycin C-treated mouse embryonic fibroblasts
(MEFs) in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
leukemia inhibitory factor, 15% heat-inactivated fetal calf serum (HyClone,
Logan, Utah), L-glutamine, and -mercaptoethanol.
Generation of Smac-deficient mice. A 129/Ola mouse phage genomic library
was screened with a murine Smac full-length cDNA probe. Restriction mapping
and sequence analysis of subcloned fragments revealed that the murine Smac
gene contains five coding exons and four introns spanning a region of at least 11
kb. The targeting vector was designed to replace exons 2 to 4 of the Smac gene
(containing the IAP binding region) with a cassette in which the neomycin
resistance gene is under the control of the PGK promoter (PGK-neo). The
diphtheria toxin A gene (DT-A) driven by the pMC1 promoter was incorporated
into the 5 end of the vector to allow for negative selection (35). The targeting
vector was linearized with NotI and electroporated into ES cells (Bio-Rad Gene
Pulser; 0.34 kV, 250 F). We obtained 380 G418-resistant ES cell colonies, which
were screened for homologous recombination by PCR. Homologous recombi-
nants were confirmed by Southern blot analysis as described previously (19) with
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the 5 external probe A depicted in Fig. 1A. Nineteen correctly targeted clones
were identified, and 3 were injected into C57BL/6J blastocysts. Three indepen-
dent Smac/ mouse strains were established by standard procedures (16).
Genotypes of mutant mice were determined by PCR and confirmed by South-
ern blot analysis of genomic DNA from tail biopsy samples. As shown in Fig. 1A,
the primers a, specific for a Smac-specific intronic sequence, and b, located in
deleted exon 2, were used to detect the wild-type allele. Primers a and c specific
for neo were used to detect the mutant allele. The sequences were as follows:
primer a, 5-TATAGAGCCCGAATGTCAGAA-3; primer b, 5-GAGACAGA
AAGGTAGAGGTGC; primer c, 5-GGTGGATGTGGAATGTGTG-3. All
data presented in this report were confirmed in at least two mutant mouse lines.
Generation of Smac/ ES cells and MEFs. To generate Smac/ ES cells,
two independent Smac/ ES cell lines were cultured in a high concentration
(4.0 to 4.5 mg/ml) of G418 for 10 days. Colonies resistant to this level of G418
were expanded, and their genotypes were determined by Southern blot analysis.
Two independent clones homozygous for the Smac mutation were selected and
used for further studies. To prepare primary MEFs, fibroblasts were established
from E14.5 F2 embryos according to standard procedures. The cells were main-
tained in DMEM supplemented with 10% fetal calf serum (FCS), L-glutamine,
and antibiotics.
In vitro assay of caspase 3 activation. The determination of caspase 3 activa-
tion was performed essentially as described previously (5). Briefly, Smac/ or
Smac/ MEFs were homogenized in buffer A (20 mM HEPES-KOH [pH 7.5],
10 mM KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride) containing 0.5% (wt/vol)
CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate} and
centrifuged at 100,000  g for 30 min at 4°C. S-100 supernatants were recovered,
and samples were stored as aliquots at 80°C. For procaspase 3 cleavage assays,
12 l of S-100 lysate (50 g of protein) was incubated with 1 g of horse heart
cytochrome c (Sigma), 1 mM dATP, and 1 mM additional MgCl2 in buffer A at
30°C for 30 or 60 min in a final volume of 20 l. The reaction mixture was then
subjected to Western blotting as described below. Recombinant Smac protein
was added to in vitro caspase assays as described previously (5).
Western blot analysis. Protein samples were prepared in buffer A containing
0.5% CHAPS and supplemented with protease inhibitor cocktail (Amersham-
Pharmacia, Piscataway, N.J.). A total of 20 g of protein per lane was fraction-
ated on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10 to 20%
polyacrylamide) gradient gel (Invitrogen, Carlsbad, Calif.), and the gel was
transferred to a polyvinylidene difluoride membrane (Millipore, Bedford,
Mass.). The blot was subsequently incubated with a rabbit polyclonal antibody
recognizing Smac (5), an antibody specifically recognizing the cleaved, active
form of caspase 3 (Cell Signaling), an antibody recognizing procaspase 3 (Trans-
duction Laboratories), anti-cIAP-1 antibody (R&D Systems), anti-cIAP-2 anti-
body (R&D Systems), anti-XIAP antibody (Transduction Laboratories), antisur-
vivin antibody (Santa Cruz Biotechnology), or anti-Omi antibody (a kind gift
from E. Alnemri, Kimmel Cancer Institute, Thomas Jefferson University, Phil-
adelphia, Pa.). Immunoblot analysis was performed with horseradish peroxidase-
conjugated goat anti-rabbit secondary antibody or goat anti-mouse secondary
antibody, and proteins were visualized with the ECL Plus enhanced chemilumi-
nescence system (Amersham-Pharmacia) according to the manufacturer’s pro-
tocol.
Apoptosis in ES cells, MEFs, and thymocytes. For ES cell apoptosis, ES cells
(105 per well) were seeded on 1% gelatinized 24-well plates in ES cell medium.
After 24 h, the cells were treated with the following stimuli to induce cell death:
UV at 60 J/m2, anisomycin (Sigma) at 30 M, adriamycin (Sigma) at 1 M, and
etoposide (Sigma) at 100 M. ES cells were harvested 8 or 24 h after the
induction of cell death. Cell viability was determined by staining with annexin-
propidium iodide (PI) (R&D Systems apoptosis detection kit; ) according to the
manufacturer’s protocol followed by flow cytometric analysis. For MEF apopto-
sis, MEFs (5  104 per well) were plated in 12-well plates and treated 24 h later
with the following apoptotic stimuli: UV light at 30, 60, 90, and 120 mJ/cm2;
staurosporine (Sigma) at 0.03, 0.1, 0.3, and 1.0 M; adriamycin at 0.3, 1, and 3
M; etoposide at 3, 10, 30, and 100 M; anisomycin at 3, 10, 30, and 100 M;
tumor necrosis factor-cycloheximide (TNF/CHX) (Sigma) at 0.1, 0.3, 1, and 3 g
of TNF per ml in the presence of 5 g of CHX per ml. For thymocyte apoptosis,
thymocytes prepared from Smac/ or Smac/ mice by standard procedures
(21) were plated at 5  106/ml in 24-well plates in RPMI containing 10% FCS.
Thymocytes were cultured for 24 h at 37°C in 5% CO2 in the presence or absence
of etoposide at 0.3, 1.0, 3, and 10 M; dexamethasone (Sigma) at 1, 3, 10, and 30
nM; or anti-Fas antibody (Jo2; BD-Pharmingen)-CHX at 0.3 g/ml, and 1 g of
anti-Fas antibody per ml in the presence of 10 g of CHX per ml. Apoptosis of
MEFs and thymocytes was determined as for ES cells.
Apoptosis in MEFs overexpressing E1A or c-Myc. To establish MEFs overex-
pressing E1A, we first transfected LPC-12S (23) into the Phoenix ecotropic
retrovirus packaging cell line to produce retrovirus carrying the E1A 12S gene
and conferring resistance to puromycin. This retrovirus was used to infect
Smac/ and Smac/ MEFs. Cells that had integrated the virus were selected
in medium containing 2.5 g of puromycin per ml (Sigma). To establish MEFs
overexpressing c-Myc, we transfected mouse cMyc/MarXII-hygro (30) into the
Phoenix ecotropic retrovirus packaging cell line to produce retrovirus carrying
the c-Myc gene and conferring resistance to hygromycin. Cells that integrated
this virus were selected in medium containing 100 g of hygromycin B per ml
(Roche, Mannheim, Germany). Selected MEFs of both retroviral types and both
genotypes were cultured in the presence or absence of adriamycin at 0.1, 0.25,
and 0.5 g/ml; TRAIL at 20 g/ml; or paclitaxel (Sigma) at 0.1, 0.5, and 1 g/ml
to induce apoptosis. After 24 h, cell viability was evaluated by trypan blue
exclusion.
Proliferation and survival of T and B cells. For activation-induced cell death
(AICD) of T cells, lymph node cells were purified with magnetic beads (21) from
Smac/ and Smac/ mice, and then incubated in six-well tissue culture plates
(6  106 cells/well) in the presence of 10 g of plate-bound anti-CD3ε (clone
145-2C11; BD-Pharmingen) per ml and interleukin-2 (50 U/ml) (Genzyme) for
48 h to induce activation. The activated cells (0.5  106) were replated in 24-well
plates precoated with 1 g of anti-CD3ε per ml and harvested 24, 48, or 72 h after
restimulation. The number of viable cells was determined by trypan blue exclu-
sion. For T-cell proliferation, purified Smac/ and Smac/ T cells were plated
into round-bottom 96-well plates (105 cells per well) in freshly prepared RPMI
1640 (10% FCS, 10 M -mercaptoethanol). The cells were stimulated with 10
ng of phorbol myristate acetate per ml (Sigma) plus 100 ng of Ca2 ionophore
A23617 per ml, 0.1 to 100 g of soluble anti-CD3ε per ml, 0.02 g of soluble
anti-CD28 per ml (clone 37.51; BD-PharMingen), or 2 g of the mitogen con-
canavalin A per ml (Amersham-Pharmacia). For B-cell proliferation, purified B
cells (105 cells per well) were stimulated with 20 g of anti-immunoglobulin M
(IgM) (61-6800; Zymed), 10 g of anti-IgM F(ab)2 fragment per ml (61-5900;
Zymed), 1 g of anti-CD40 per ml (clone HM40; BD-PharMingen), or 2 g of
lipopolysaccharide per ml (Sigma). Cells were stimulated in triplicate for differ-
ent time periods and pulsed for the last 12 to 18 h with 1 Ci of [3H]thymidine
per well (NEN, Boston, Mass.). Labeled cells were harvested with a Filtermate-
196 harvester (Canberra Packard, Mississauga, Canada), and thymidine incor-
poration was determined with a Matrix-996 direct counter (Canberra Packard).
Histological analysis. Tissues were fixed in freshly prepared 4% paraformal-
dehyde (Sigma) overnight at 4°C. Samples were dehydrated in an ethanol series
and embedded in wax. Sections were stained with either hematoxylin and eosin
(H&E) or by terminal deoxynucleotide transferase nick-end labeling (TUNEL)
staining. TUNEL staining was performed with the Roche In Situ Cell Death
Detection kit according to the manufacturer’s instructions.
Induction of apoptosis in the liver. Young adult mice (8 to 10 weeks old) were
injected intraperitoneally with anti-Fas antibody (Jo2; BD-Pharmingen) at a
dose of 10 or 100 g per animal. Some animals were monitored for survival,
while others were killed 3 h after injection for histological analysis of their
tissues. Sections of liver were stained with H&E or TUNEL as described above.
Numbers of TUNEL-positive cells were counted in at least five fields per liver.
RESULTS
Targeted disruption of the Smac gene in mice. To determine
the physiological role of Smac in vivo, we used homologous
recombination in ES cells to disrupt the Smac gene and gen-
erate Smac knockout mice (Fig. 1A). The targeting vector was
designed to replace most of the Smac coding region, including
exons 2 to 4, with the PGK-neo cassette. A polymorphism was
discovered in a BamHI restriction site in the Smac locus when
DNA from the C57BL6/J and 129/Ola genetic backgrounds
was compared. Probe A indicated in Fig. 1A recognizes a 7-kb
fragment from the 129/Ola wild-type allele, a 12.0-kb fragment
from the C57BL6/J wild-type allele, and a 5.0-kb fragment
from the targeted allele. We obtained 19 independent ES cell
clones carrying the mutated Smac allele, and 3 (sm-7, sm-24,
and sm-33) were injected into C57BL/6J blastocysts to gener-
ate chimeric mice. F1 heterozygotes originating from the sm-24
or sm-33 clones were intercrossed to produce the F2 progeny
3510 OKADA ET AL. MOL. CELL. BIOL.
FIG. 1. Targeting of the murine Smac gene by homologous recombination. (A) Schematic representation of the wild-type mouse Smac locus
(top), the targeting construct (middle), and the mutated Smac allele (bottom). The coding exons are shown as clear boxes. Exons 2 to 4 were
replaced with PGK-neo, and DT-A was added for negative selection. The 5-flanking probe A used for Southern blot analysis is shown, as are the
predicted sizes of the hybridizing fragments. The primer pairs used for PCR (a and b or a and c) are also indicated. R, EcoRI; B, BamHI; X, XbaI;
N, NotI. (B) Southern blot analysis of Smac-deficient ES cells and mice. (Left panel) DNA prepared from C57BL6/J (/) mice and F1 offspring
(/ and /) of chimeric mice. (Right panel) DNA was from 129/Ola ES cells (/), Smac/ ES cell clones, C57BL6/J (/) mice, and F2
offspring (/, /, and /) of intercrosses of Smac mutant F1 mice. In all cases, tail genomic DNA was digested with BamHI and hybridized
to probe A. (C) Western blot analysis of Smac protein expression. Protein samples were prepared from Smac/, Smac/, and Smac/ MEFs and
incubated with anti-Smac antibody. Actin was used as the loading control. (D) Genotypic analysis of F2 littermates by PCR. PCR was performed
on genomic tail DNA templates with primer pair a and b to detect the wild-type allele (W) or primers a and c to detect the mutant allele (M).
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analyzed in this report. Figure 1B shows Southern blot analyses
of DNA from C57BL6/J wild-type mice, C57BL6/J-129/Ola F1
offspring, 129/Ola ES cells, and F2 offspring from F1 inter-
crosses.
To confirm that the knockout allele was a null mutation,
MEFs were prepared from Smac/, Smac/, and Smac/
littermates and lysates were subjected to Western blotting to
detect Smac expression. As shown in Fig. 1C, Smac/ MEFs
do not express Smac. Genotypic analysis of F2 offspring was
confirmed by PCR (Fig. 1D). Of 243 F2 pups, 65 were wild type
(26.7%), 117 were heterozygous for the mutation (48.2%), and
61 were homozygous mutants (25.1%), consistent with the
ratio expected from Mendelian inheritance. Both male and
female Smac/ mice were healthy and fertile, and F3
Smac/ offspring obtained by homozygous intercrosses were
also healthy. Both Smac/ and Smac/ mice developed nor-
mally and did not exhibit any obvious macroscopic or micro-
scopic abnormalities (data not shown). Aged mice (more than
12 months of age) did not show any sign of anomalies, such as
autoimmune disease or tumor formation (data not shown).
Caspase 8 activation in vitro is impaired in Smac/ cell
lysates. The Smac protein is localized in the soluble membrane
fraction of cell lysates, which promotes caspase 3 activation in
a manner dependent on caspase 9, Apaf-1, and cytochrome c
(5). We therefore compared in vitro cleavage of procaspase 3
in cell lysates prepared from Smac/ or Smac/ MEFs.
Caspase 3 activation was induced by the addition of dATP and
cytochrome c to cell lysates, and the presence of cleaved, en-
dogenous caspase 3 was detected by immunoblotting with an-
tibody specifically recognizing active caspase 3. While pro-
caspase 3 cleavage could be detected within 30 min in Smac/
lysates, activated caspase 3 was not observed in Smac/ ly-
sates even after 60 min (Fig. 2A). To confirm that this pheno-
type was caused by the loss of Smac, we reconstituted the
Smac/ lysate with recombinant Smac protein (5). Pro-
caspase 3 cleavage was restored in the Smac/ lysate in a
dose-dependent manner (Fig. 2B). To exclude the possibility
that the loss of Smac affected the protein levels of the IAPs, we
compared the levels of several IAPs in Smac/ and Smac/
lysates by Western blotting. Equivalent amounts of c-IAP1,
c-IAP2, XIAP, and survivin were detected in the presence and
absence of Smac (data not shown). We also investigated the
expression of Omi/HtrA2, a recently reported functional ho-
mologue of Smac (10, 14, 25, 27). Equivalent amounts of Omi
protein were detected in Smac/ and Smac/ lysates (data
not shown). From these observations, we conclude that we
have introduced a functionally null mutation into the Smac
gene and confirm that Smac potentiates procaspase 3 cleavage
in vitro as previously reported (5).
Induction of apoptosis is normal in primary and trans-
formed Smac/ cells. Since procaspase 3 cleavage is a defin-
ing event in most instances of apoptosis, we investigated
whether the loss of Smac had any effect on apoptosis induced
in MEFs subjected to UV irradiation. It has previously been
shown that overexpression of Smac itself does not induce ap-
optosis in cells, but rather sensitizes them to UV-induced cell
death (5). We subjected Smac/ and Smac/ primary MEFs
to UV irradiation and assessed viability. As shown in Fig. 3A,
similar levels of PCD were induced in Smac/ and Smac/
MEFs at 24 h after UV irradiation. It has been reported that
Smac starts to be released from the mitochondria into the
cytosol within the first few hours after UV irradiation (5). To
examine the possibility that Smac might inhibit procaspase 3
cleavage at early time points, we compared the amount of
FIG. 2. Smac deficiency impairs caspase 3 cleavage in vitro. (A) Im-
paired in vitro caspase 3 cleavage in Smac/ MEFs. Lysates of
Smac/ or Smac/ MEFs were incubated in vitro with the indicated
assay reagents, and the cleavage of procaspase 3 was detected by
Western blotting with antibodies recognizing either the cleaved (ac-
tive) form of caspase 3 or procaspase 3. One of the representative
results from three independent samples is shown. cyt C, cytochrome c.
(B) Restoration of procaspase 3 cleavage by addition of recombinant
Smac protein. Lysates of Smac/ MEFs were incubated with the
indicated reagents plus 1 nM to 1 M recombinant Smac protein.
Detection of activated caspase 3 was as for panel A.
FIG. 3. Smac-deficient cells respond normally to apoptotic stimuli. (A) PCD induced by UV irradiation in primary MEFs. Smac/ or Smac/
MEFs were subjected to UV irradiation, and cell viability was determined by annexin-PI staining at 24 h. (B) Procaspase 3 cleavage in UV-treated
MEFs. Protein samples were prepared from Smac/ or Smac/ MEFs at 0, 4, 8, 12, or 16 h after UV irradiation. The amount of active caspase
3 was determined by Western blot analysis as for Fig. 2A. (C to F) Effect of Smac deficiency on PCD induced by various other stimuli in MEFs
and other cell types. MEFs (C), ES cells (D), thymocytes (E), and E1A- or c-Myc-overexpressing MEFs (F) were treated with the indicated
reagents for 24 h, and cell viability was determined by annexin-PI staining. The data shown are means  standard deviations of triplicate
measurements and are representative of three experiments with similar results.
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active caspase 3 accumulated in Smac/ and Smac/ MEFs
at 0, 4, 8, 12, and 16 h after UV irradiation. No difference in the
level of active caspase 3 was detected at any time point (Fig.
3B), indicating that UV-induced apoptosis of primary MEFs is
not affected by the loss of Smac.
We next examined a range of chemical agents to determine
whether Smac is associated with PCD induced only in certain
cell types or only by certain apoptotic stimuli. Staurosporine,
adriamycin, anisomycin, etoposide, and TNF/CHX all induced
PCD equally in Smac/ and Smac/ MEFs (Fig. 3C) and
also in Smac/ and Smac/ ES cells (Fig. 3D [TNF/CHX
not tested]). Similarly, Smac/ thymocytes treated with eto-
poside, dexamethasone, or Fas/CHX underwent normal PCD
(Fig. 3E). PCD induced by staurosporine or by UV or gamma
irradiation was also indistinguishable in thymocytes from
Smac/ and Smac/ mice (data not shown). Thus, despite
the involvement of IAPs in apoptosis, loss of Smac has no
effect on PCD induced in these cell types under these circum-
stances.
Oncogenes can sensitize cells to apoptosis mediated by the
mitochondrial pathway (7, 8). We therefore infected Smac/
and Smac/ MEFs with retroviruses causing overexpression
of the oncogene c-Myc or E1A. These cells were then treated
with adriamycin, TRAIL, or paclitaxel to induce PCD. Cells of
both genotypes became equally hypersensitive to apoptotic
stimuli (Fig. 3F). This result was somewhat unexpected in view
of the fact that transformed caspase 3-deficient MEFs are
resistant to PCD induced by these stimuli (32). Our data sug-
gest that other molecules must be able to substitute for Smac
in the induced PCD of both primary and oncogene-overex-
pressing cells.
Smac-deficient T and B cells show normal proliferation and
survival. In the absence of caspase 3, T cells are less suscep-
tible to AICD (30), and activated B cells hyperproliferate in
response to mitogenic stimulation (M. Woo, C. Furlonger, R.
Hakem, C. Paige, and T. W. Mak, submitted for publication).
Since Smac deficiency decreased the amount of activated
caspase 3 in MEFs, we examined AICD of T cells and prolif-
eration of both activated T and B cells. T cells were activated
in vitro as described in Materials and Methods, and cell via-
bility at 24, 48, and 72 h was evaluated by trypan blue exclusion.
No significant differences in AICD were observed between
Smac/ and Smac/ T cells (Fig. 4A). Proliferation of T and
B cells activated as described in Materials and Methods was
measured by [3H]thymidine incorporation at 24, 48, or 72 h
after activation for T cells and at 24, 48, or 96 h after activation
for B cells. There was no difference between Smac/ and
Smac/ cells in [3H]thymidine incorporation by either acti-
vated T or B cells (Fig. 4B). These results show that Smac does
not affect either cell proliferation or survival of activated lym-
phocytes.
Fas-mediated apoptosis occurs normally in Smac/ hepa-
tocytes. It has been reported that Fas-mediated hepatocyte cell
death is delayed in caspase 3-deficient mice (31). Since caspase
3 activation was impaired in vitro in the absence of Smac, we
investigated the role of Smac in Fas-mediated PCD in vivo by
injecting Smac/ mice with agonistic anti-Fas antibody. Both
Smac/ and Smac/ mice died within 3 or 10 h after injec-
tion of 100 or 10 g of anti-Fas antibody, respectively, with
similar kinetics (Fig. 5A). Hepatocyte apoptosis was verified by
staining liver sections with H&E (Fig. a, c, and e) or TUNEL
(Fig. b, d, and f). No statistically significant differences in
numbers of TUNEL-positive cells were observed between
Smac/ and Smac/ mice livers (data not shown). Similar
results were obtained when apoptosis was induced in heart or
kidney by injecting adriamycin (12) or tunicamycin (15), re-
spectively (data not shown).
DISCUSSION
Our finding in vivo that targeted disruption of the Smac gene
has no effect on apoptosis stands in sharp contrast to previous
evidence established by biochemical, cell biological and struc-
tural analyses that favor a role for Smac/DIABLO in PCD (5,
29). One of the best examples of this apparent contradiction in
our report is the discrepancy between the results of the in vitro
caspase 3 activation assay and the phenotype of Smac/ cells.
We were able to demonstrate differences in procaspase 3 cleav-
age in Smac/ and Smac/ MEF lysates, but could not
detect any differences in induced PCD in MEFs. The simplest
explanation for this discrepancy is that a functional homologue
of Smac exists in vivo, but was not present or functional in cell
lysates. We found equivalent protein expression of Omi/
HtrA2, a functional homologue of Smac, in wild-type and
Smac-deficient cell lysates, but the possibility remains that Omi
may have been inactive or only weakly active under the in vitro
assay conditions used. In this context, it is noteworthy that
some activated caspase 3 was detected in Smac/ samples
after prolonged incubation (data not shown); however, this
amount of activated caspase 3 was still significantly less than
that in the wild type.
The phenotype of Smac-deficient mice could easily be ac-
counted for if Omi was fully active and sufficient to compensate
for the loss of Smac in vivo. It will therefore be useful to
generate double mutant mice lacking both Smac and Omi to
clarify the precise physiological role of the Smac-mediated
pathway. Alternatively, other mitochondrial proapoptotic mol-
ecules, such as AIF (24), NOXA (17), and p53AIP (18), may
be able to compensate for a loss of Smac function in certain
contexts in vivo. Finally, the phenotype of Smac/ mice could
result if Smac does not play an essential role in the common
apoptotic machinery, but instead participates in regulating
PCD only in a specific situation or in tissues yet to be identi-
fied.
FIG. 4. Activated Smac-deficient T and B cells show normal proliferation and survival in culture. (A) Activation-induced cell death in T cells.
T cells prepared from either Smac/ or Smac/ mice were activated in vitro and restimulated with anti-CD3ε. The number of viable cells
remaining was determined at the indicated time points (solid bars, /; open bars, /). (B) Proliferation of T and B cells. T or B cells prepared
from either Smac/ or Smac/ mice were stimulated in vitro with the indicated stimuli. Cell proliferation was determined by measuring
[3H]thymidine incorporation (cpm) at the indicated time points (solid bars,/; open bars,/). The data shown are means standard deviations
of triplicate measurements. Experiments were repeated three times with similar results.
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A role for Smac in apoptosis is not evident from our gene
disruption study. However, no obvious abnormalities were
found in Smac/ mice, meaning that investigation of alterna-
tive functions for the Smac protein will require extensive ef-
forts to find specific conditions under which loss of Smac re-
sults in pathology. The generation of combined mutants by
crossing Smac-deficient mice with transgenic mice prone to
cancer formation or autoimmune disease might help to reveal
covert phenotypes. On the other hand, the phenotype of Smac-
deficient mice presented in this study strongly suggests the
existence of a redundant molecule or molecules. Research to
identify such molecules may bring to light new regulatory
mechanisms of apoptosis, which could ultimately lead to novel
therapeutic targets for diseases caused by the deregulation of
apoptosis.
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FIG. 5. Fas-mediated apoptosis is intact in the liver of Smac-deficient mice. (A) Survival curve of mice injected with anti-Fas antibody. Either
10 or 100 g of anti-Fas antibody was injected into the intraperitoneal cavity of Smac/ or Smac/ mice (n  3 per group per dose). One
experiment representative of five independent trials is shown (solid symbols, 100 g; open symbols, 10 g) (B) Histological analysis of livers of mice
injected with anti-Fas antibody. Liver sections were prepared 3 h after Smac/ (a and b), Smac/ (c and d), and Smac/ (e and f) mice were
injected with 100 g of anti-Fas antibody. Sections were stained with H&E (a, c, and e) or by TUNEL (b, d, and f).
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